INTRODUCTION
Surgical trauma to the eye initiates an inflammatory reaction. This reaction includes the release of prostaglandins and the recruitment of neutrophils and macrophages to the site of trauma [1] . Although usually selflimited, post-operative ocular inflammation after cataract surgery can be associated with complications, including corneal edema, spikes in intraocular pressure (IOP), cystoid macular edema (CME), and posterior capsule opacification [1] . As most patients expect 20/20 vision after cataract surgery without any complications, the use of prophylactic anti-inflammatory agents is a standard practice. Topical corticosteroids are routinely used in the treatment of post-operative inflammation following cataract surgery [2] [3] [4] [5] as well as after most other ocular surgical procedures [6] [7] [8] [9] . Corticosteroids reduce intraocular inflammation, which is most often measured by anterior segment cell and flare reaction. They also alleviate associated symptoms, such as photophobia, swelling, pain, and tenderness.
At a histological level, corticosteroids suppress cellular infiltration, capillary dilation, the proliferation of fibroblasts, collagen deposition, and eventually scar formation [10] .
At a cellular level, they stabilize intracellular and extracellular membranes, and increase the synthesis of anti-inflammatory lipocortins.
Lipocortins, in turn, block phospholipase A 2 , the enzyme responsible for conversion of phospholipids to arachidonic acid, the first step in the inflammatory cascade ( Fig. 1 ) [11] [12] [13] . Corticosteroids mediate their antiinflammatory effects primarily through the glucocorticoid receptor by direct and indirect actions at the genomic level [14] . Recent work suggests that the activated corticosteroidreceptor complex also elicits nongenomic effects, particularly in the inhibition of vasodilation, vascular permeability, and migration of leukocytes [14] .
Although topical ocular corticosteroids are a vital component of the treatment of postoperative inflammation, their prolonged use can produce side effects, such as increased IOP, cataract formation (in phakic individuals), and lowered resistance to infection [1, 11, [15] [16] [17] . Research shows that elevated IOP, if left untreated, may lead to progressive optic nerve damage and glaucomatous visual field defects, ultimately culminating in corticosteroid-induced glaucoma [18] . The mechanism whereby topical corticosteroids increase IOP is not fully Fig. 1 The inflammatory pathway. PG prostaglandin understood. The glucocorticoid receptor is involved in multiple, diverse signaling pathways, and it is thought that steroidinduced IOP elevation, particularly that observed with long-term use or high doses of corticosteroids, is the result of upregulation or repression of one or more genes unrelated to the indication being treated [19] . Most studies implicate trabecular meshwork (TM) cells and myocilin gene expression in the mechanism of corticosteroid-induced IOP elevation.
Corticosteroids appear to decrease the outflow of aqueous humor by inhibiting the degradation and/or enhancing the deposition of extracellular matrix material within the TM and/or cross-linking of actin fibers between TM cells [20] . The TM accounts for the majority of drainage from the eye; it appears to be this resistance to aqueous outflow (caused by changes to the TM and its extracellular matrix) that eventually leads to an increase in IOP.
Indeed, early ultrastructural studies revealed an increase in extracellular ground substance of the corneo-scleral trabeculum in steroidinduced glaucoma [21] . Clark and Wordinger [22] suggested that structural changes in the TM, in turn, result in corticosteroid-induced ocular hypertension, which can progress to secondary iatrogenic open-angle glaucoma.
Myocilin, initially referred to as TM-inducible glucocorticoid response or TIGR gene product, is a 55-kDa protein induced after exposure of TM cells to dexamethasone for 2-3 weeks, which is also closely associated with decreased aqueous humor outflow and steroid-induced IOP increase [23, 24] . Different mutations within the myocilin gene lead to a variety of glaucoma phenotypes in both juvenile and 
TOPICAL OCULAR CORTICOSTEROIDS: DIFFERENCES IN REPORTING INTRAOCULAR PRESSURE EFFECTS ACROSS STUDIES
As indicated previously, while the efficacy of topical ocular corticosteroids in the treatment of ocular inflammation has been shown, they also have the potential of increasing IOP [1, 11, 13, 15, 16, 19, [27] [28] [29] [30] [31] . However, to date, meaningful comparisons of the potential for corticosteroid-induced increase in IOP with different corticosteroids have been hampered by a lack of a standard format for testing and reporting clinically significant IOP elevations [18] . In the mid-1960s, Becker used absolute IOP as the criterion, with 20 mmHg being the lower limit of a clinically significant response, while
Armaly [32, 33] All treatments were effective in the primary outcome measure-reducing inflammation after phacoemulsification. Mean IOP was higher in the prednisolone group when compared with the ketorolac group on day 21 (14.6 vs. 12.2 mmHg, respectively; P = 0.016) but did not differ from the fluorometholone group (13.8 mmHg). One eye in the prednisolone group had an IOP of 32 mmHg on day 21 and was terminated from the study. There were no between-treatment differences in the mean IOP at any visits, with IOP ranging from 11.1 to 14.0 and 10.5-14.7 mmHg in the prednisolone acetate and rimexolone groups, respectively.
Difluprednate, a derivative of prednisolone that is difluorinated at the C6 and C9 positions [4] , is approved for treating post-operative inflammation in the United States and some countries in the European Union. Originally developed for dermatologic applications, it was also found to rapidly penetrate the corneal epithelium [4] . Korenfeld 
STUDIES IN STEROID RESPONDERS
Some patients have a documented history of IOP increase in response to corticosteroid treatment, in which a small dose of corticosteroid or a short duration of treatment may result in disproportionate increases in IOP. First documented by Armaly and Becker in the 1960s [32, 70, 71] , steroid responders generally constitute 18-36% of the general population [19] . Corticosteroid effects on IOP in such patients are generally reversible; IOP will usually return to pretreatment levels within 1-3 weeks if the treatment is discontinued [72] . Nevertheless, careful monitoring of IOP is essential in such individuals. Longer axial length has been identified as a risk factor for steroid-induced IOP elevation [28] . In addition,
patients with primary open-angle glaucoma, family history of glaucoma and status as a glaucoma suspect are also at higher risk for developing corticosteroid-induced ocular hypertension [26, 67] . Most prospective studies reviewed in the previous sections would have excluded known steroid responders, as the risk of developing a clinically significant change in IOP would have been considered too high. However, several published studies report on the corticosteroid-induced IOP response in known steroid responders. These studies are extremely valuable in differentiating the relative IOP effects among corticosteroids as any differences will be more pronounced in this study population.
Cantrill et al. [73] Bartlett et al. [16] 
CONCLUSION
The likelihood of a clinically significant increase in IOP (C10 mmHg) is an important consideration when deciding on which topical corticosteroid is best suited to a patient. 
